ISSCR Warns NIH Against Stem Cell Registry Pause Citing Major Risks to Clinical Research Pipeline

Stem cell experts warn the NIH that pausing the hESC registry risks billions in investment and halts clinical trials for Parkinson’s and diabetes.

By: AXL Media

Published: Apr 25, 2026, 10:26 AM EDT

Source: Information for this report was sourced from International Society for Stem Cell Research

Defending the Foundation of Modern Regenerative Medicine

In a formal response to a Request for Information (RFI) from the National Institutes of Health, the International Society for Stem Cell Research (ISSCR) has voiced strong opposition to a recent pause on new submissions to the federal Human Embryonic Stem Cell Registry. The society, which represents nearly 5,000 scientists and clinicians, argues that hESCs remain the irreplaceable benchmark for pluripotency, providing the essential ability to self-renew and transform into any human cell type. According to the ISSCR, the current federal considerations to reduce reliance on these cells threaten to destabilize a research ecosystem that has taken decades and substantial public funding to build.

The Strategic Value of Existing Federal Repositories

Decades of NIH investment have established a sophisticated network of cell line repositories and standardized protocols that serve as the backbone for global biomedical innovation. These resources have moved beyond basic science and are currently fueling a robust pipeline of advanced clinical applications. As of late 2024, nearly half of all global clinical trials involving hESC-derived products were conducted within the United States, underscoring the nation's leadership in the field. These trials target some of the most challenging medical conditions, including Type 1 diabetes and drug-resistant epilepsy, which are now reaching critical late-stage testing phases.

Benchmarks for New Technology and Drug Discovery

While newer methodologies like induced pluripotent stem cells (iPSCs) and computational modeling have expanded the scientific toolkit, the ISSCR emphasizes that they do not serve as replacements for embryonic lines. Instead, hESCs are used as the primary standard against which all other cellular models are validated for accuracy and safety. Furthermore, these cells are vital for the development of new approach methodologies (NAMs) intended to reduce the industry's dependence on animal testing. By providing stable and well-characterized reference materials, hESCs ensure that preclinical drug discovery remains both rigorous and reproducible.